Poor Ovarian Reserve Clinical Trial
Official title:
Effect of Polyethylene Glycol Recombinant Human Growth Hormone Injection on the IVF/ICSI Outcome of Patients With Poor Ovarian Reserve
Declined fertility and ovarian reserve in older women are associated with lower density of Growth hormone (GH) receptors and dysregulation in GH secretion. GH can regulate the expression of growth hormone receptor and strengthen the function of mitochondria, which could improve the quality of the female oocyte. In this study, a prospective randomized control will be conducted to explore the effect of GH adjuvant therapy on clinical outcome of in vitro fertilization.
Eligible subjects will be randomly assigned into either the study groups (receive somatropin co-treatment) or the control group (without sopmatropin treatment). Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) for approximately 6 weeks, i.e. from the beginning of preceding menstruation cycle until the day of ovum pickup. Both groups will receive a similar common protocol for ovarian stimulation. In vitro fertilization with or without intracytoplasmic sperm injection will be performed according to semen parameters. All embryos will undergo culture for blastocyst and the obtained blastocysts will be vitrified for deferred frozen embryo transfer. The Blastocyst formation rate will be the primary outcome measure. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01204840 -
Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)
|
Phase 2 | |
| Completed |
NCT04797377 -
Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response
|
N/A | |
| Completed |
NCT04224818 -
Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders
|
Phase 3 | |
| Recruiting |
NCT05602090 -
Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials
|
Phase 2/Phase 3 |